Refine search

Search Disease/ Diagnostics

Search term:

Results 201 - 300 of 2610

download as CSV

download all results as CSV

EC Number	Disease	PubMed ID	Title of Publication	Category	Confidence Level
3.5.3.1	arginase deficiency	33561495	Arginase-1 deficiency in neural cells does not contribute to neurodevelopment or functional outcomes after sciatic nerve injury.	causal interaction unassigned	4 0
3.5.3.1	arginase deficiency	33614409	Physical, cognitive, and social status of patients with urea cycle disorders in Japan.	causal interaction unassigned	2 0
3.5.3.1	arginase deficiency	33732618	Arginine to ornithine ratio as a diagnostic marker in patients with positive newborn screening for hyperargininemia.	causal interaction diagnostic usage ongoing research unassigned	4 4 2 0
3.5.3.1	arginase deficiency	33840128	Long-term outcome of urea cycle disorders: Report from a nationwide study in Japan.	causal interaction unassigned	3 0
3.5.3.1	arginase deficiency	33995244	Review of Multi-Modal Imaging in Urea Cycle Disorders: The Old, the New, the Borrowed, and the Blue.	causal interaction ongoing research therapeutic application unassigned	4 4 2 0
3.5.3.1	arginase deficiency	34232532	Role of liver transplantation in urea cycle disorders: Report from a nationwide study in Japan.	unassigned	0
3.5.3.1	arginase deficiency	34343381	Case series of Arginase 1 deficiency: Expanding the spectrum in hyperargininemia.	causal interaction ongoing research therapeutic application unassigned	4 4 1 0
3.5.3.1	arginase deficiency	34471603	Creatine metabolism in patients with urea cycle disorders.	causal interaction diagnostic usage unassigned	4 2 0
3.5.3.1	arginase deficiency	100148568	Isotropic growth of spores and salt tolerance in Aspergillus nidulans	ongoing research unassigned	2 0
3.5.3.1	argininosuccinate lyase deficiency	15164414	Genetic approach to prenatal diagnosis in urea cycle defects.	causal interaction unassigned	4 0
3.5.3.1	argininosuccinate lyase deficiency	23324524	Ammonia Control in Children Ages 2 Months through 5 Years with Urea Cycle Disorders: Comparison of Sodium Phenylbutyrate and Glycerol Phenylbutyrate.	diagnostic usage unassigned	2 0
3.5.3.1	argininosuccinate lyase deficiency	27215558	Improving long term outcomes in urea cycle disorders-report from the Urea Cycle Disorders Consortium.	causal interaction unassigned	4 0
3.5.3.1	argininosuccinate lyase deficiency	29423830	Biochemical markers and neuropsychological functioning in distal urea cycle disorders.	causal interaction unassigned	4 0
3.5.3.1	argininosuccinate lyase deficiency	33614409	Physical, cognitive, and social status of patients with urea cycle disorders in Japan.	causal interaction unassigned	2 0
3.5.3.1	argininosuccinate lyase deficiency	33840128	Long-term outcome of urea cycle disorders: Report from a nationwide study in Japan.	causal interaction unassigned	3 0
3.5.3.1	argininosuccinate synthase deficiency	15164414	Genetic approach to prenatal diagnosis in urea cycle defects.	causal interaction unassigned	4 0
3.5.3.1	argininosuccinate synthase deficiency	20025860	Clinical and biochemical characteristics of patients with urea cycle disorders in a developing country.	causal interaction unassigned	2 0
3.5.3.1	argininosuccinate synthase deficiency	23324524	Ammonia Control in Children Ages 2 Months through 5 Years with Urea Cycle Disorders: Comparison of Sodium Phenylbutyrate and Glycerol Phenylbutyrate.	diagnostic usage unassigned	2 0
3.5.3.1	argininosuccinate synthase deficiency	27215558	Improving long term outcomes in urea cycle disorders-report from the Urea Cycle Disorders Consortium.	causal interaction unassigned	4 0
3.5.3.1	argininosuccinate synthase deficiency	28608518	Liver transplantation may prevent neurodevelopmental deterioration in high-risk patients with urea cycle disorders.	causal interaction unassigned	3 0
3.5.3.1	argininosuccinate synthase deficiency	29423830	Biochemical markers and neuropsychological functioning in distal urea cycle disorders.	causal interaction unassigned	4 0
3.5.3.1	argininosuccinate synthase deficiency	33614409	Physical, cognitive, and social status of patients with urea cycle disorders in Japan.	causal interaction unassigned	2 0
3.5.3.1	argininosuccinate synthase deficiency	33840128	Long-term outcome of urea cycle disorders: Report from a nationwide study in Japan.	causal interaction unassigned	3 0
3.5.3.1	argininosuccinate synthase deficiency	34232532	Role of liver transplantation in urea cycle disorders: Report from a nationwide study in Japan.	unassigned	0
3.5.3.1	Argininosuccinic Aciduria	7717428	Prenatal diagnosis of the urea cycle diseases: a survey of the European cases.	causal interaction diagnostic usage unassigned	2 3 0
3.5.3.1	Argininosuccinic Aciduria	14162426	ARGININOSUCCINIC ACIDURIA. ARGININOSUCCINASE AND ARGINASE IN HUMAN BLOOD CELLS.	ongoing research unassigned	4 0
3.5.3.1	Argininosuccinic Aciduria	15164414	Genetic approach to prenatal diagnosis in urea cycle defects.	causal interaction unassigned	4 0
3.5.3.1	Argininosuccinic Aciduria	23324524	Ammonia Control in Children Ages 2 Months through 5 Years with Urea Cycle Disorders: Comparison of Sodium Phenylbutyrate and Glycerol Phenylbutyrate.	diagnostic usage unassigned	2 0
3.5.3.1	Argininosuccinic Aciduria	27215558	Improving long term outcomes in urea cycle disorders-report from the Urea Cycle Disorders Consortium.	causal interaction unassigned	4 0
3.5.3.1	Argininosuccinic Aciduria	29423830	Biochemical markers and neuropsychological functioning in distal urea cycle disorders.	causal interaction unassigned	4 0
3.5.3.1	Argininosuccinic Aciduria	33614409	Physical, cognitive, and social status of patients with urea cycle disorders in Japan.	causal interaction unassigned	2 0
3.5.3.1	Argininosuccinic Aciduria	33840128	Long-term outcome of urea cycle disorders: Report from a nationwide study in Japan.	causal interaction unassigned	3 0
3.5.3.1	Argininosuccinic Aciduria	34471603	Creatine metabolism in patients with urea cycle disorders.	causal interaction diagnostic usage unassigned	4 2 0
3.5.3.1	Arrhythmias, Cardiac	25814956	Arginase induction and activation during ischemia and reperfusion and functional consequences for the heart.	causal interaction unassigned	1 0
3.5.3.1	Arthritis	12415579	Increased expression of arginase II in patients with different forms of arthritis. Implications of the regulation of nitric oxide.	causal interaction diagnostic usage ongoing research unassigned	2 4 4 0
3.5.3.1	Arthritis	21484767	Endothelial dysfunction in rat adjuvant-induced arthritis: Up-regulation of the vascular arginase pathway.	diagnostic usage ongoing research unassigned	1 4 0
3.5.3.1	Arthritis	22647483	Treatment with the arginase inhibitor Nw-hydroxy-nor-L-arginine restores endothelial function in rat adjuvant-induced arthritis.	causal interaction ongoing research therapeutic application unassigned	2 1 4 0
3.5.3.1	Arthritis	27267914	Soluble Siglec-9 suppresses arthritis in a collagen-induced arthritis mouse model and inhibits M1 activation of RAW264.7 macrophages.	causal interaction diagnostic usage ongoing research unassigned	1 2 1 0
3.5.3.1	Arthritis	28298526	The AP-1 Transcription Factor c-Jun Promotes Arthritis by Regulating Cyclooxygenase-2 and Arginase-1 Expression in Macrophages.	unassigned	0
3.5.3.1	Arthritis	29024866	Diclofenac but not celecoxib improves endothelial function in rheumatoid arthritis: A study in adjuvant-induced arthritis.	causal interaction ongoing research therapeutic application unassigned	1 3 1 0
3.5.3.1	Arthritis	30119237	Modulatory effect of eugenol on arginase, nucleotidase, and adenosine deaminase activities of platelets in a carrageenan-induced arthritis rat model: A possible anti-arthritic mechanism of eugenol.	ongoing research unassigned	1 0
3.5.3.1	Arthritis	30887278	Vascular Arginase Is a Relevant Target to Improve Cerebrovascular Endothelial Dysfunction in Rheumatoid Arthritis: Evidence from the Model of Adjuvant-Induced Arthritis.	causal interaction therapeutic application unassigned	2 4 0
3.5.3.1	Arthritis	30990796	Transcription factor Fra-1 targets arginase-1 to enhance macrophage-mediated inflammation in arthritis.	causal interaction therapeutic application unassigned	2 1 0
3.5.3.1	Arthritis, Gouty	30585453	[Effect of Electroacupuncture on Synovial M 1/M 2 Macrophage Polarization in Rats with Acute Gouty Arthritis].	ongoing research unassigned	3 0
3.5.3.1	Arthritis, Reactive	26829838	[SPECIES COMPOSITION OF INFECTIOUS FACTORS THAT CAUSE THE REACTIVE ARTHRITIS DEVELOPMENT AND THEIR EFFECT ON ARGINASE-NO-SYNTHASE REGULATORY SYSTEM OF PERIPHERAL BLOOD LYMPHOCYTES].	causal interaction diagnostic usage therapeutic application unassigned	4 2 1 0
3.5.3.1	Arthritis, Rheumatoid	11593962	Arginase levels are increased in patients with rheumatoid arthritis.	causal interaction diagnostic usage ongoing research unassigned	4 4 1 0
3.5.3.1	Arthritis, Rheumatoid	12415579	Increased expression of arginase II in patients with different forms of arthritis. Implications of the regulation of nitric oxide.	causal interaction diagnostic usage ongoing research unassigned	2 4 4 0
3.5.3.1	Arthritis, Rheumatoid	17435254	Relationship between synovial fluid and plasma manganese, arginase, and nitric oxide in patients with rheumatoid arthritis.	causal interaction diagnostic usage ongoing research unassigned	3 4 3 0
3.5.3.1	Arthritis, Rheumatoid	29884228	Elevated levels of plasma symmetric dimethylarginine and increased arginase activity as potential indicators of cardiovascular comorbidity in rheumatoid arthritis.	causal interaction diagnostic usage unassigned	4 4 0
3.5.3.1	Arthritis, Rheumatoid	30592386	Changes in the pattern of cytokine production from peripheral blood mononuclear cells in patients with rheumatoid arthritis treated with infliximab and their relation to plasma arginase activity.	causal interaction diagnostic usage ongoing research unassigned	1 2 4 0
3.5.3.1	Arthritis, Rheumatoid	30887278	Vascular Arginase Is a Relevant Target to Improve Cerebrovascular Endothelial Dysfunction in Rheumatoid Arthritis: Evidence from the Model of Adjuvant-Induced Arthritis.	causal interaction therapeutic application unassigned	2 4 0
3.5.3.1	Arthritis, Rheumatoid	33483748	TNF? induces endothelial dysfunction in rheumatoid arthritis via LOX-1 and arginase 2: reversal by monoclonal TNF? antibodies.	unassigned	0
3.5.3.1	Asthma	643733	[Carbamoyl ornithine transferase, arginase and cobalt-activated acylase in patients during asthma attacks or patients with respiratory failure]	causal interaction ongoing research unassigned	2 1 0
3.5.3.1	Asthma	7413457	[Sputum arginase activity in bronchial asthma]	diagnostic usage therapeutic application unassigned	2 1 0
3.5.3.1	Asthma	12023942	Increased arginase activity underlies allergen-induced deficiency of cNOS-derived nitric oxide and airway hyperresponsiveness.	causal interaction ongoing research therapeutic application unassigned	4 4 1 0
3.5.3.1	Asthma	12813015	Arginase: marker, effector, or candidate gene for asthma?	causal interaction unassigned	4 0
3.5.3.1	Asthma	12813022	Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis.	ongoing research unassigned	1 0
3.5.3.1	Asthma	12967769	Arginase and asthma: novel insights into nitric oxide homeostasis and airway hyperresponsiveness.	causal interaction ongoing research therapeutic application unassigned	4 2 4 0
3.5.3.1	Asthma	14607075	cNOS-iNOS paradigm and arginase in asthma.	unassigned	0
3.5.3.1	Asthma	14618299	Glucocorticoid inhibition of interleukin-4 (IL-4) and interleukin-13 (IL-13) induced up-regulation of arginase in rat airway fibroblasts.	ongoing research unassigned	4 0
3.5.3.1	Asthma	15070820	Decreased arginine bioavailability and increased serum arginase activity in asthma.	causal interaction diagnostic usage ongoing research unassigned	4 4 2 0
3.5.3.1	Asthma	15187136	Enhancer-mediated control of macrophage-specific arginase I expression.	causal interaction therapeutic application unassigned	3 1 0
3.5.3.1	Asthma	15621923	Relationship among manganese, arginase, and nitric oxide in childhood asthma.	causal interaction diagnostic usage ongoing research unassigned	4 4 4 0
3.5.3.1	Asthma	15755639	Synthesis and evaluation of new omega-borono-alpha-amino acids as rat liver arginase inhibitors.	causal interaction therapeutic application unassigned	3 2 0
3.5.3.1	Asthma	15939249	Evaluation of oxidative-antioxidative status and the L-arginine-nitric oxide pathway in asthmatic patients.	causal interaction unassigned	4 0
3.5.3.1	Asthma	16141432	Arginase activity differs with allergen in the effector phase of ovalbumin- versus trimellitic anhydride-induced asthma.	causal interaction therapeutic application unassigned	4 1 0
3.5.3.1	Asthma	16185164	The therapeutic potential of drugs targeting the arginase pathway in asthma.	causal interaction therapeutic application unassigned	4 4 0
3.5.3.1	Asthma	16257997	Inhibition of phosphodiesterase 4 amplifies cytokine-dependent induction of arginase in macrophages.	causal interaction therapeutic application unassigned	4 4 0
3.5.3.1	Asthma	16387594	Genetic polymorphisms in arginase I and II and childhood asthma and atopy.	causal interaction ongoing research therapeutic application unassigned	4 2 1 0
3.5.3.1	Asthma	16409014	New Strategies for the Treatment of Pulmonary Hypertension in Sickle Cell Disease : The Rationale for Arginine Therapy.	causal interaction unassigned	3 0
3.5.3.1	Asthma	16409620	Arginase strongly impairs neuronal nitric oxide-mediated airway smooth muscle relaxation in allergic asthma.	causal interaction therapeutic application unassigned	3 1 0
3.5.3.1	Asthma	17015747	Inhibition of arginase I activity by RNA interference attenuates IL-13-induced airways hyperresponsiveness.	causal interaction ongoing research therapeutic application unassigned	4 1 2 0
3.5.3.1	Asthma	17291856	Influence of cigarette smoke on the arginine pathway in asthmatic airways: increased expression of arginase I.	causal interaction ongoing research therapeutic application unassigned	4 2 3 0
3.5.3.1	Asthma	17410056	[Arginine metabolism in bronchial asthma]	causal interaction ongoing research unassigned	4 2 0
3.5.3.1	Asthma	17691958	Mouse models of asthma: can they give us mechanistic insights into the role of nitric oxide?	causal interaction ongoing research unassigned	1 1 0
3.5.3.1	Asthma	17890324	Transiently, paralleled upregulation of arginase and nitric oxide synthase and the effect of both enzymes on the pathology of asthma.	ongoing research unassigned	1 0
3.5.3.1	Asthma	18410920	Arginine homeostasis in allergic asthma.	causal interaction therapeutic application unassigned	4 4 0
3.5.3.1	Asthma	18437360	Arginase and pulmonary diseases.	causal interaction diagnostic usage ongoing research therapeutic application	4 4 4 1
3.5.3.1	Asthma	18439639	Arginases I and II in lungs of ovalbumin-sensitized mice exposed to ovalbumin: sources and consequences.	causal interaction ongoing research unassigned	4 2 0
3.5.3.1	Asthma	18583571	Arginase inhibition protects against allergen-induced airway obstruction, hyperresponsiveness, and inflammation.	causal interaction therapeutic application unassigned	4 4 0
3.5.3.1	Asthma	18635886	Alterations of the arginine metabolome in asthma.	diagnostic usage ongoing research unassigned	2 1 0
3.5.3.1	Asthma	18703795	Elevated asymmetric dimethylarginine alters lung function and induces collagen deposition in mice.	causal interaction therapeutic application unassigned	4 3 0
3.5.3.1	Asthma	18768883	Inhibition of arginase activity enhances inflammation in mice with allergic airway disease, in association with increases in protein S-nitrosylation and tyrosine nitration.	causal interaction unassigned	2 0
3.5.3.1	Asthma	18991648	Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders.	causal interaction unassigned	4 0
3.5.3.1	Asthma	19027033	Arginase enzymes in isolated airways from normal and nitric oxide synthase 2-knockout mice exposed to ovalbumin.	ongoing research therapeutic application unassigned	4 1 0
3.5.3.1	Asthma	19093830	Probing the specificity determinants of amino acid recognition by arginase.	causal interaction therapeutic application unassigned	4 4 0
3.5.3.1	Asthma	19229984	Asthma management: reinventing the wheel in sickle cell disease.	causal interaction diagnostic usage therapeutic application unassigned	4 2 1 0
3.5.3.1	Asthma	19251784	L-Arginine deficiency causes airway hyperresponsiveness after the late asthmatic reaction.	ongoing research unassigned	2 0
3.5.3.1	Asthma	19281908	Roles of arginase variants, atopy, and ozone in childhood asthma.	causal interaction unassigned	4 0
3.5.3.1	Asthma	19286931	Functionally Important Role for Arginase 1 in the Airways Hyperresponsiveness of Asthma.	causal interaction therapeutic application unassigned	3 4 0
3.5.3.1	Asthma	19486531	Bone marrow cell derived arginase I is the major source of allergen-induced lung arginase but is not required for airway hyperresponsiveness, remodeling and lung inflammatory responses in mice.	causal interaction unassigned	4 0
3.5.3.1	Asthma	19542246	Mepacrine inhibits subepithelial fibrosis by reducing the expression of arginase and TGF-beta1 in an extended subacute mouse model of allergic asthma.	unassigned	0
3.5.3.1	Asthma	19703164	Arginase: a key enzyme in the pathophysiology of allergic asthma opening novel therapeutic perspectives.	causal interaction therapeutic application unassigned	4 4 0
3.5.3.1	Asthma	20124949	Arginase 1 and arginase 2 variations associate with asthma, asthma severity and beta2 agonist and steroid response.	causal interaction ongoing research therapeutic application unassigned	4 2 1 0
3.5.3.1	Asthma	20382750	Direct inhibition of arginase attenuated airway allergic reactions and inflammation in a Dermatophagoides farinae-induced NC/Nga mouse model.	causal interaction ongoing research therapeutic application unassigned	1 3 4 0
3.5.3.1	Asthma	20441173	2-Aminoimidazole Amino Acids as Inhibitors of the Binuclear Manganese Metalloenzyme Human Arginase I.	causal interaction therapeutic application unassigned	4 2 0
3.5.3.1	Asthma	21039185	High Serum Arginase I Levels in Asthma: its Correlation with High-Sensitivity C-Reactive Protein.	causal interaction diagnostic usage unassigned	4 1 0
3.5.3.1	Asthma	21078495	Simvastatin inhibits goblet cell hyperplasia and lung arginase in a mouse model of allergic asthma: a novel treatment for airway remodeling?	therapeutic application unassigned	4 0
3.5.3.1	Asthma	21271567	Increased expression of arginase I and II in allergic nasal mucosa.	causal interaction unassigned	4 0
3.5.3.1	Asthma	21291525	Augmentation of arginase 1 expression by exposure to air pollution exacerbates the airways hyperresponsiveness in murine models of asthma.	causal interaction ongoing research unassigned	2 1 0

Results 201 - 300 of 2610

download as CSV

download all results as CSV